Evidence map›Paper›PMID 40365033›Full record

ArticleIJTLD open2025

Patient and provider preferences for long-acting TB preventive therapy.

M Vermeulen, K K Scarsi, R Furl, H Sayles, M J Anderson, S Valawalkar, A Kadam, S R Cox, V Mave, M Barthwal and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJTLD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Preventing Multidrug-Resistant Tuberculosis: The Dawn of a New Era.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

M VermeulenDepartment of Medicine and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town, South Africa.
K K ScarsiCollege of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
R FurlCollege of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
H SaylesCollege of Public Health, University of Nebraska Medical Center, Omaha, NE, USA.
M J AndersonCollege of Public Health, University of Nebraska Medical Center, Omaha, NE, USA.
S ValawalkarJohns Hopkins India, Center for Infectious Diseases in India (CIDI), Pune, India.
A KadamJohns Hopkins India, Center for Infectious Diseases in India (CIDI), Pune, India.
S R CoxJohns Hopkins Bloomberg School of Public Health, Epidemiology, Baltimore, MD, USA.
V MaveJohns Hopkins India, Center for Infectious Diseases in India (CIDI), Pune, India.
M BarthwalDr. D. Y. Patil Medical College, Hospital and Research Centre, Department of Pulmonary Medicine, Pune, Maharashtra, India.
C SchutzDepartment of Medicine and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town, South Africa.
A WardDepartment of Medicine and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town, South Africa.
J Dountio OfimboudemTreatment Action Group, New York, NY, USA.
G MeintjesDepartment of Medicine and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town, South Africa.
S RannardDepartment of Chemistry, Centre of Excellence for Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, UK.
A OwenDepartment of Pharmacology and Therapeutics, Centre of Excellence for Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, UK.
S SwindellsCollege of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.

Funding

The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)R24AI118397 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Charles W. Flexner · 2015 to 2026
$9.4M
NIAID NIH HHS R24 AI118397
6 · The paper itself

Abstract

backgroundTuberculosis preventive therapy (TPT) is critical for TB elimination but is underutilised. Long-acting (LA) TPT can potentially improve linkage to care, treatment adherence and outcomes.

methodsWe conducted a cross-sectional in-person survey in two high TB burden countries to evaluate preferences and concerns about LA formulations for TPT. The survey compared oral pills to LA injections, implants, and microarray patches (MAPs). A parallel online survey of healthcare providers (HCPs) in low- and middle-income countries (LMICs) assessed the perceived feasibility of implementation. Data were summarised by descriptive statistics.

resultsWe recruited 409 patients (India,

conclusionInjectable LA-TPT may be highly acceptable and feasible if concerns surrounding cost, effectiveness, and safety are addressed.

Indexed as

feasibilitylong-actingpreferencespreventiontuberculosis

Identifiers

PMID40365033
PMCPMC12068448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.